A systematic review assessing the under-representation of elderly adults in COVID-19 trials.
COVID-19
Clinical trials, systematic review
Elderly
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
20 12 2020
20 12 2020
Historique:
received:
30
06
2020
accepted:
09
12
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Coronavirus disease (COVID-19) has caused a pandemic threatening millions of people worldwide. Yet studies specifically assessing the geriatric population are scarce. We aimed to examine the participation of elderly patients in therapeutic or prophylactic trials on COVID-19. In this review, randomized controlled trials (RCTs; n = 12) comparing therapeutic or prophylactic interventions registered on preprint repositories and/or published since December 2019 were analyzed. We searched in PubMed, leading journals websites, and preprint repositories for RCTs and large observational studies. We aimed to describe the age of included patients, the presence of an upper age limit and of adjusted analyses on age, any exclusion criteria that could limit participation of elderly adults such as comorbidities, cognitive impairment, limitation of life expectancy; and the assessment of long-term outcomes such as the need of rehabilitation or institutionalization. Mean participant ages were reported and compared with observational studies. Twelve RCTs assessing drug therapy for COVID-19 were included. Mean age of patients included in RCTs was 56.3 years. An upper age limit was applied in three published trials (25%) and in 200/650 (31%) trials registered at clinicaltrials.gov . One trial reported a subgroup analysis in patients ≥65. Patients were excluded for liver-function abnormalities in eight trials, renal disease in six, cardiac disease or risk of torsade de pointes in five, and four for cognitive or mental criteria, which are frequent comorbidities in the oldest patients. Only three trials allowed a family member to provide consent. Patients enrolled in RCTs were on average 20 years younger than those included in large (n ≥ 1000) observational studies. Seven studies had as their primary outcome a clinical endpoint, but none reported cognitive, functional or quality of life outcomes or need for rehabilitation or long-term care facility placement. Elderly patients are clearly underrepresented in RCTs, although they comprise the population hardest hit by the COVID-19 pandemic. Long-term outcomes such as the need of rehabilitation or institutionalization were not reported. Future investigations should target specifically this vulnerable population.
Sections du résumé
BACKGROUND
Coronavirus disease (COVID-19) has caused a pandemic threatening millions of people worldwide. Yet studies specifically assessing the geriatric population are scarce. We aimed to examine the participation of elderly patients in therapeutic or prophylactic trials on COVID-19.
METHODS
In this review, randomized controlled trials (RCTs; n = 12) comparing therapeutic or prophylactic interventions registered on preprint repositories and/or published since December 2019 were analyzed. We searched in PubMed, leading journals websites, and preprint repositories for RCTs and large observational studies. We aimed to describe the age of included patients, the presence of an upper age limit and of adjusted analyses on age, any exclusion criteria that could limit participation of elderly adults such as comorbidities, cognitive impairment, limitation of life expectancy; and the assessment of long-term outcomes such as the need of rehabilitation or institutionalization. Mean participant ages were reported and compared with observational studies.
RESULTS
Twelve RCTs assessing drug therapy for COVID-19 were included. Mean age of patients included in RCTs was 56.3 years. An upper age limit was applied in three published trials (25%) and in 200/650 (31%) trials registered at clinicaltrials.gov . One trial reported a subgroup analysis in patients ≥65. Patients were excluded for liver-function abnormalities in eight trials, renal disease in six, cardiac disease or risk of torsade de pointes in five, and four for cognitive or mental criteria, which are frequent comorbidities in the oldest patients. Only three trials allowed a family member to provide consent. Patients enrolled in RCTs were on average 20 years younger than those included in large (n ≥ 1000) observational studies. Seven studies had as their primary outcome a clinical endpoint, but none reported cognitive, functional or quality of life outcomes or need for rehabilitation or long-term care facility placement.
CONCLUSIONS
Elderly patients are clearly underrepresented in RCTs, although they comprise the population hardest hit by the COVID-19 pandemic. Long-term outcomes such as the need of rehabilitation or institutionalization were not reported. Future investigations should target specifically this vulnerable population.
Identifiants
pubmed: 33342426
doi: 10.1186/s12877-020-01954-5
pii: 10.1186/s12877-020-01954-5
pmc: PMC7749979
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
538Références
Ann Intensive Care. 2020 Apr 20;10(1):45
pubmed: 32307593
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Chin Med J (Engl). 2020 May 5;133(9):1132-1134
pubmed: 32149772
Complement Ther Clin Pract. 2020 May;39:101166
pubmed: 32379637
PLoS One. 2012;7(3):e33559
pubmed: 22479411
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Med (N Y). 2020 Dec 18;1(1):105-113.e4
pubmed: 32838353
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Int J Mol Sci. 2020 Apr 10;21(7):
pubmed: 32290293
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Heart Rhythm. 2020 Sep;17(9):1425-1433
pubmed: 32407884
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105
pubmed: 32284951
Eur J Pharm Sci. 2020 Oct 25;:105631
pubmed: 33115675
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Br J Clin Pharmacol. 2020 May 8;:
pubmed: 32384171
J Am Geriatr Soc. 2020 May;68(5):922-925
pubmed: 32207542
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
PLoS One. 2020 Feb 12;15(2):e0228952
pubmed: 32050005
N Engl J Med. 2020 Oct 8;383(15):1406-1408
pubmed: 32668133
Clin Microbiol Infect. 2013 Jun;19(6):510-2
pubmed: 23397980
Geriatrics (Basel). 2020 Apr 26;5(2):
pubmed: 32357575
Med (N Y). 2020 Dec 18;1(1):114-127.e3
pubmed: 32838355
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Am Geriatr Soc. 2015 Feb;63(2):233-43
pubmed: 25688601